Sanofi-Aventis Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Sanofi-Aventis on May 5, 2008, covering events in April 2008. The filing incorporates two press releases issued in late April 2008 regarding a U.S. government contract and first-quarter 2008 financial performance.
Key Financial Metrics
The filing references a specific contract value but does not provide consolidated revenue, profit, cash flow, or margin figures within the text of the Form 6-K itself.
- Contract Value: $192 million for H5N1 bulk vaccine antigen accepted by the U.S. Government.
- Other Metrics: The filing text does not provide clear values for total revenue, net income, operating margins, debt levels, or liquidity positions. These details are contained in the referenced press release (Exhibit 99.2) but are not reproduced in this document.
Material Changes and Developments
- Government Contract: On April 28, 2008, the U.S. Government accepted $192 million worth of H5N1 bulk vaccine antigen from Sanofi Pasteur for the pandemic stockpile.
- Financial Performance: On April 30, 2008, the company reported "encouraging" first-quarter 2008 results, though specific comparative figures versus the prior period are not detailed in this filing.
Outlook, Risks, and Management Commentary
Management characterized the first-quarter 2008 results as "encouraging." The filing highlights the successful delivery of pandemic vaccine materials as a significant operational milestone. No specific risks, contingencies, or forward-looking guidance numbers are explicitly stated in the body of this Form 6-K.
Key Facts for Investor Verification
- Verify the specific revenue and profit figures for Q1 2008 in the full text of the April 30, 2008 press release (Exhibit 99.2).
- Confirm the impact of the $192 million H5N1 vaccine contract on the company's backlog and future revenue recognition.
- Review the full Q1 2008 report for details on organic growth rates and margin trends compared to Q1 2007.